DiaSorin LIAISON Q.S.E.T. Device Plus, REF 319060; intended for use in the preparation of human s...
FDA Device Recall #Z-0677-2025 — Class II — November 7, 2024
Recall Summary
| Recall Number | Z-0677-2025 |
| Classification | Class II — Moderate risk |
| Date Initiated | November 7, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Diasorin Inc. |
| Location | Stillwater, MN |
| Product Type | Devices |
| Quantity | 21905 units |
Product Description
DiaSorin LIAISON Q.S.E.T. Device Plus, REF 319060; intended for use in the preparation of human stool specimens
Reason for Recall
Customer complaints were received alleging leaking devices and insufficient buffer volume. Diasorin's internal investigation determined that 0.14% of the LIAISON Q.S.E.T. Device Plus in the lots identified have loose clear caps, which may allow buffer to leak from the tube. A stool sample prepared with less than the correct amount of buffer may result an incorrectly high patient result.
Distribution Pattern
Worldwide
Lot / Code Information
UDI/DI 80567713190605F, Lot Numbers: 225084, 232094, 234114, 259144, 221214, 252244, 230094, 224124, 205144, 228174, 228224, 223274, 219104, 217134, 233154, 236174, 224244, 232294, 229224, 251234, 221294, 210204, 223244, 222314
Other Recalls from Diasorin Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0815-2024 | Class II | DiaSorin LIAISON HSV-2 Type Specific IgG, REF 3... | Dec 13, 2023 |
| Z-1342-2021 | Class II | LIAISON 1-84 PTH Assay - Product Usage: is an i... | Nov 23, 2020 |
| Z-2936-2020 | Class II | Parvovirus B19 IgG EIA kit Part No. V519IGUS | Jul 17, 2020 |
| Z-0645-2017 | Class II | LIAISON Estradiol II Gen, 310680, 310680-CN ... | Jul 13, 2016 |
| Z-1464-2015 | Class II | DiaSorin, PRO-Trac II Tacrolimus ELISA kit, REF... | Mar 16, 2015 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.